Exelixis, Inc. (EXEL) Presents at Stifel 2026 Targeted Oncology Virtual Forum Transcript

Exelixis, Inc. (EXEL) Presents at Stifel 2026 Targeted Oncology Virtual Forum Transcript

Seeking Alpha • 5 hours ago

EXEL Collaborates With MRK for Late-Stage Colorectal Cancer Study

Exelixis teams up with Merck to advance zanzalintinib in a phase III colorectal cancer study, expanding its pipeline beyond Cabometyx.

Zacks Investment Research • 6 hours ago

Exelixis, Inc. (EXEL) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Exelixis, Inc. (EXEL) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Seeking Alpha • May 19, 2026

Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that the company has entered into a clinical development collaboration with Merck, known as MSD outside of the United States and Canada, to supply KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous administration in combination with zanzalintinib in STELLAR-316, a planned phase 3 pivotal trial in patients with resected stage II/III colorectal cancer (CRC). Under the terms of th.

Business Wire • May 19, 2026

Prediction: This Stock Could Double By 2031

Exelixis's main product should continue driving growth through the end of the decade. The company is close to earning approval for a medicine that will take up the mantle thereafter.

The Motley Fool • May 15, 2026

Exelixis (EXEL) is a Top-Ranked Momentum Stock: Should You Buy?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • May 15, 2026

Exelixis, Inc. (EXEL) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Exelixis, Inc. (EXEL) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • May 12, 2026

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in May: BofA Securities Health Care Conference 2026: Exelixis is scheduled to present at 1:00 p.m. ET / 10:00 a.m. PT on Tuesday, May 12 in Las Vegas. 2026 RBC Capital Markets Global Healthcare Conference: Exelixis is scheduled to present at 9:00 a.m. ET / 6:00 a.m. PT on Tuesday, May 19 in New York City. 2026 Stifel Vir.

Business Wire • May 7, 2026

Exelixis, Inc. (EXEL) Q1 2026 Earnings Call Transcript

Exelixis, Inc. (EXEL) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 6, 2026

EXEL Q1 Earnings Top Estimates, Colorectal Cancer Drug in Focus

EXEL beats Q1 EPS estimates on lower costs and buybacks but misses on revenues; Cabometyx sales lag estimates as pipeline progress and new buybacks stay in focus.

Zacks Investment Research • May 6, 2026